April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost ...

A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.

Swedish biotech OncoZenge (Nasdaq: ONCOZ) has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge ...

The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...

US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal ...

An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary ...

Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...

A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. Findings ...

The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...